ChemoCentryx

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

Quest Diagnostics

ChemoCentryx initiates phase II CCX140 trial

Monday, December 12, 2011 12:40 PM

ChemoCentryx has initiatied a phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease (diabetic nephropathy). CCX140 is a novel CCR2 inhibitor with a pharmacological profile unlike that of other CCR2 compounds that have been known to be tested by other sponsors. CCX140 works by blocking the infiltration and activation of certain populations of monocyte and macrophages and other cells bearing CCR2 that occurs during inflammation. This mechanism of action provides selective treatment of the disease without compromising other immune functions.

More... »


ChemoCentryx initiates phase II CCX168 trial

Monday, October 17, 2011 11:49 AM

ChemoCentryx has initiated a phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.  CCX168 specifically targets the C5a receptor (C5aR), a potent pro-inflammatory mediator that is involved in AAV as well as several other autoimmune diseases.  This randomized, double-blind, placebo-controlled trial will evaluate the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis while assessing the potential for reducing or eliminating the use of corticosteroids in these patients.

More... »

ChemoCentrx’s diabetes trial meets primary endpoint

Thursday, September 15, 2011 12:10 PM

ChemoCentryx has reported that its novel, orally active CCR2 antagonist, CCX140-B, demonstrated an excellent safety profile and exhibited clear signs of biological and clinical effect in a phase II study in patients with type 2 diabetes on stable doses of metformin. 

More... »

ChemoCentryx reports CCX140 meets primary endpoint

Wednesday, June 29, 2011 12:53 PM

ChemoCentryx said CCX140, an orally active CCR2 antagonist, successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a phase II study in patients with type 2 diabetes on stable doses of metformin.  

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs